<DOC>
	<DOCNO>NCT01539655</DOCNO>
	<brief_summary>Study healthy volunteer assess effect omeprazole ranitidine pharmacokinetics vandetanib</brief_summary>
	<brief_title>Study Healthy Volunteers Assess Effect Omeprazole Ranitidine Pharmacokinetics Vandetanib</brief_title>
	<detailed_description>A Phase I , Randomized , Open-label , Single-center Study Assess Pharmacokinetics Vandetanib ( CAPRELSA ) Healthy Subjects Single Oral Dose Vandetanib 300 mg Administered Alone Combination Omeprazole Ranitidine</detailed_description>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<criteria>Provision sign date , write informed consent prior studyspecific procedure Volunteers must males female age 18 50 year weight least 50 kg body mass index ( BMI ) 18 30 kg/m2 Inclusive Females must negative pregnancy test screen admission study center Females must lactate must non childbearing potential define postmenopausal documentation irreversible surgical sterilization . History clinically significant disease disorder gastrointestinal , hepatic , renal skin disease . History severe allergy/hypersensitivity ongoing allergy/hypersensitivity Volunteers smoke 5 cigarette per day unable refrain smoking resident study center Screening blood pressure great 140/90 mmHg and/or rest heart rate le 45 beat per minute ( repeat test allow Investigator 's discretion Clinically significant abnormal12lead ECG assess Investigator QTcF interval great 450 m Any positive result screen serum hepatitis B surface antigen , hepatitis C antibody Human immunodeficiency virus ( HIV ) , positive screen drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>vandetanib</keyword>
	<keyword>omeprazole</keyword>
	<keyword>ranitidine</keyword>
</DOC>